M&A Deal Summary |
|
|---|---|
| Date | 2021-08-09 |
| Target | CSI Laboratories |
| Sector | Life Science |
| Buyer(s) | Fulgent |
| Sellers(s) | Synergy Capital Investments |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 1,184 |
| Revenue | 289M USD (2023) |
Fulgent is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next-generation sequencing with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service, and automated lab services. Fulgent was founded in 2011 and is based in El Monte, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector (Life Science) | 1 of 3 |
| Type (Add-on Acquisition) | 1 of 3 |
| State (Georgia) | 1 of 1 |
| Country (United States) | 1 of 3 |
| Year (2021) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-18 |
Inform Diagnostics
Irving, Texas, United States Inform Diagnostics is a provider of anatomic pathology services primarily in the fields of gastroenterology, dermatology, hematology, breast health, and urology. The company's team of more than 90 distinguished expert subspecialists utilizes state-of-the-art pathology laboratories to serve more than 5,500 patients every day. Inform Diagnostics continuously improves diagnostic accuracy through consensus-based terminology and criteria, rigorous quality assurance, daily consensus conferences, extensive educational and training activities, and close relationships with clinical partners. Inform Diagnostics was formed in 1996 and is based in Irving, Texas. |
Buy | $170M |
| Category | Private Equity Firm |
|---|---|
| Founded | 2016 |
| Size | Small |
| Type | Sector Agnostic |
Synergy Capital Investments is a private equity firm that specializes in the acquisition, joint venture, and management of small to mid-market operating businesses. Synergy seeks value-add transactions where it can partner with management to pursue growth initiatives and opportunities. Synergy Capital Investments was established in 2016 and is headquartered in Atlanta, Georgia.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Add-on Acquisition) | 1 of 1 |
| State (Georgia) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2021) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-09 |
CSI Laboratories
Alpharetta, Georgia, United States CSI Laboratories provides a client- and patient-focused model of cancer diagnostic testing for pathologists, community hospitals and their patients. CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, next-generation sequencing, and consultations to hematopathology and surgical pathology clients. CSI Laboratories was founded in 1997 and is based in Alpharetta, Georgia. |
Buy | - |
